Skip to content
Clinical Trials – home

Find therapies in clinical trials near you

recruiting
3 975
countries
28
conditions
2 106

21 trials match your criteria

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Study of Blinatumomab Treatment in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, or Granulomatosis with Polyangiitis: Safety and Effectiveness Evaluation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients 55+ with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab

Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Blinatumomab

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Asparaginase
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab

Acute lymphocytic leukaemia

Not yet recruiting

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.